NBI 27914 hydrochloride

Pricing Availability   Qty
Description: Selective non-peptide CRF1 antagonist
Chemical Name: 5-Chloro-N-(cyclopropylmethyl)-2-methyl-N-propyl-N'-(2,4,6-trichlorophenyl)-4,6-pyrimidinediamine hydrochloride
Purity: ≥99% (HPLC)
Citations (12)
Literature (3)

Biological Activity for NBI 27914 hydrochloride

NBI 27914 hydrochloride is a selective, non-peptide corticotropin-releasing factor1 (CRF1) receptor antagonist (Ki = 1.7 nM); has no activity at CRF2 receptors. Blocks behavioral seizures in vivo.

Compound Libraries for NBI 27914 hydrochloride

NBI 27914 hydrochloride is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.

Technical Data for NBI 27914 hydrochloride

M. Wt 470.66
Formula C18H20Cl4N4.HCl
Storage Store at RT
Purity ≥99% (HPLC)
CAS Number 1215766-76-9
PubChem ID 45073446
Smiles Cl.CCCN(CC1CC1)C1=C(Cl)C(NC2=C(Cl)C=C(Cl)C=C2Cl)=NC(C)=N1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for NBI 27914 hydrochloride

Solvent Max Conc. mg/mL Max Conc. mM
ethanol 43.42 100
DMSO 43.42 100

Preparing Stock Solutions for NBI 27914 hydrochloride

The following data is based on the product molecular weight 470.66. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.12 mL 10.62 mL 21.25 mL
5 mM 0.42 mL 2.12 mL 4.25 mL
10 mM 0.21 mL 1.06 mL 2.12 mL
50 mM 0.04 mL 0.21 mL 0.42 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Product Datasheets for NBI 27914 hydrochloride

Certificate of Analysis / Product Datasheet
Select another batch:

References for NBI 27914 hydrochloride

References are publications that support the biological activity of the product.

Baram et al (1997) The CRF1 receptor mediates the excitatory actions of cortico. releasing factor (CRF) in the developing rat brain: in vivo evidence using a novel, selective, non-peptide CRF receptor antagonist. Brain Res. 770 89 PMID: 9372207

Chen et al (1996) Design and synthesis of a series of non-peptide high-affinity human corticotropin-releasing factor1 receptor antagonists. J.Med.Chem. 39 4358 PMID: 8893829

McCarthy et al (1999) Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications. Curr.Pharm.Des. 5 289 PMID: 10213797

If you know of a relevant reference for NBI 27914 hydrochloride, please let us know.

View Related Products by Target

View Related Products by Product Action

View all CRF1 Receptor Antagonists

Keywords: NBI 27914 hydrochloride, NBI 27914 hydrochloride supplier, Selective, non-peptide, CRF1, antagonists, Corticotropin-Releasing, Factor1, Receptors, NBI27914, hydrochloride, 1591, Tocris Bioscience

12 Citations for NBI 27914 hydrochloride

Citations are publications that use Tocris products. Selected citations for NBI 27914 hydrochloride include:

Navarro et al (2015) Orexin-corticotropin-releasing factor receptor heteromers in the ventral tegmental area as targets for cocaine. Stroke 35 6639 PMID: 25926444

Lowery-Gionta et al (2012) Corticotropin releasing factor signaling in the central amygdala is recruited during binge-like ethanol consumption in C57BL/6J mice. J Neurosci 32 3405 PMID: 22399763

Silberman and Winder (2013) Corticotropin releasing factor and catecholamines enhance glutamatergic neurotransmission in the lateral subdivision of the central amygdala. Neuropharmacology 70 316 PMID: 23470280

Liu et al (2010) Differential actions of urocortins on neurons of the myenteric division of the enteric nervous system in guinea pig distal colon. Br J Pharmacol 159 222 PMID: 20002096

Do you know of a great paper that uses NBI 27914 hydrochloride from Tocris? Please let us know.

Reviews for NBI 27914 hydrochloride

There are currently no reviews for this product. Be the first to review NBI 27914 hydrochloride and earn rewards!

Have you used NBI 27914 hydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

GPCR Product Listing

GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling
Peptide Hormone Receptors Product Listing

Peptide Hormone Receptors Product Listing

A collection of over 200 products for peptide hormone receptors, the listing includes research tools for the study of:

  • Anterior Pituitary Regulation
  • Blood Pressure Regulation
  • Feeding and Appetite Regulation
  • Glucose Regulation
  • Peptide Hormone Processing
Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.